10 faktów na temat pantoprazolu Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2019
Słowa kluczowe:
pantoprazol, gastroprotekcja, inhibitory pompy protonowej, zastosowanie w leczeniu
##plugins.themes.bootstrap3.article.main##
Abstrakt
Pantoprazol jest lekiem z grupy inhibitorów pompy protonowej o szerokim zastosowaniu w leczeniu chorób górnego odcinka przewodu pokarmowego, zależnych od wydzielania kwasu solnego w żołądku. Stanowi lek pierwszego rzutu ze względu na wysoką skuteczność w ich leczeniu oraz łagodzeniu związanych z nimi dolegliwości. Wykazuje małe ryzyko interakcji, dzięki czemu może być bezpiecznie stosowany u osób z wieloma chorobami przewlekłymi, w tym wśród pacjentów stosujących leczenie przeciwpłytkowe, osób starszych, z niewydolnością nerek i niewydolnością wątroby w stopniu A i B według skali Childa–Pugha.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Szczypek, M., & Gietka, P. (2019). 10 faktów na temat pantoprazolu . Medycyna Faktów , 12(1(42), 59-62. https://doi.org/10.24292/01.MF.0119.10
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Poole P.: Pantoprazole. Am. J. Health Syst. Pharm. 2001; 58(11): 999-1008.
2. Cheer S.M., Prakash A., Faulds D. et al.: Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs 2003; 63: 101-133.
3. Calabrese C., Fabbri A., Di Febo G.: Long-term management of GERD in the elderly with pantoprazole. Clin. Interv. Aging 2007; 2(1): 85-92.
4. Lanza F.L.: A guideline for the treatment and prevention of NSAID-induced ulcers. Am. J. Gastroenterol. 1998; 93: 2037-2046.
5. Hartmann M., Theiss U., Huber R. et al.: Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment. Pharmacol. Ther. 1996; 10: 359-366.
6. Devault K.R.: Pantoprazole: a proton pump inhibitor with oral and intravenous formulations. Expert. Rev. Gastroenterol. Hepatol. 2007; 1: 197-205.
7. Angiolillo D.J., Gibson C.M., Cheng S. et al.: Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin. Pharmacol. Ther. 2011; 89(1): 65-74.
8. Harmsze A.M., van Werkum J.W., Taubert D. et al.: Esomeprazole but not pantoprazole is associated with lower plasma concentrations of clopidogrel’s active metabolite. Ann. Pharmacother. 2011; 45(4): 542-543.
9. Siller-Matula J.M., Spiel A.O., Lang I.M. et al.: Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am. Heart J. 2009; 157(1): 148.e1-5.
10. Scott S.A., Owusu Obeng A., Hulot J.S.: Antiplatelet drug interactions with proton pump inhibitors. Expert Opin. Drug Metab. Toxicol. 2013; 10(2): 175-189.
11. Malfertheiner P., Megraud F., O’Morain C.A. et al.; on behalf of the European Helicobacter and Microbiota Study Group and Consensus panel: Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut 2017; 66: 6-30.
12. Pellicano R., Zagari R.M., Zhang S. et al.: Pharmacological considerations and step-bystep proposal for the treatment of Helicobacter pylori infection in the year 2018. Minerva Gastroenterol. Dietol. 2018; 64: 310-321.
13. Blume H., Donath F., Warnke A. et al.: Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006; 29(9): 769-784.
14. Wedemeyer R.S., Blume H.: Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014; 37(4): 201-211.
15. Mathews S., Reid A., Tian C., Cai Q.: An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease. Clin. Exp. Gastroenterol. 2010; 3: 11-16.
16. Chiba N., De Gara C.J., Wilkinson J.M. et al.: Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-1810.
17. Scholten T.: Long-term management of gastroesophageal reflux disease with pantoprazole. Ther. Clin. Risk Manag. 2007; 3(2): 231-243.
18. Sachs G., Shin J.M.: The basis of differentiation of PPIs. Drugs of Today 2004; 40(supl. A): 9-14.
2. Cheer S.M., Prakash A., Faulds D. et al.: Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs 2003; 63: 101-133.
3. Calabrese C., Fabbri A., Di Febo G.: Long-term management of GERD in the elderly with pantoprazole. Clin. Interv. Aging 2007; 2(1): 85-92.
4. Lanza F.L.: A guideline for the treatment and prevention of NSAID-induced ulcers. Am. J. Gastroenterol. 1998; 93: 2037-2046.
5. Hartmann M., Theiss U., Huber R. et al.: Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment. Pharmacol. Ther. 1996; 10: 359-366.
6. Devault K.R.: Pantoprazole: a proton pump inhibitor with oral and intravenous formulations. Expert. Rev. Gastroenterol. Hepatol. 2007; 1: 197-205.
7. Angiolillo D.J., Gibson C.M., Cheng S. et al.: Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin. Pharmacol. Ther. 2011; 89(1): 65-74.
8. Harmsze A.M., van Werkum J.W., Taubert D. et al.: Esomeprazole but not pantoprazole is associated with lower plasma concentrations of clopidogrel’s active metabolite. Ann. Pharmacother. 2011; 45(4): 542-543.
9. Siller-Matula J.M., Spiel A.O., Lang I.M. et al.: Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am. Heart J. 2009; 157(1): 148.e1-5.
10. Scott S.A., Owusu Obeng A., Hulot J.S.: Antiplatelet drug interactions with proton pump inhibitors. Expert Opin. Drug Metab. Toxicol. 2013; 10(2): 175-189.
11. Malfertheiner P., Megraud F., O’Morain C.A. et al.; on behalf of the European Helicobacter and Microbiota Study Group and Consensus panel: Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut 2017; 66: 6-30.
12. Pellicano R., Zagari R.M., Zhang S. et al.: Pharmacological considerations and step-bystep proposal for the treatment of Helicobacter pylori infection in the year 2018. Minerva Gastroenterol. Dietol. 2018; 64: 310-321.
13. Blume H., Donath F., Warnke A. et al.: Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006; 29(9): 769-784.
14. Wedemeyer R.S., Blume H.: Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014; 37(4): 201-211.
15. Mathews S., Reid A., Tian C., Cai Q.: An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease. Clin. Exp. Gastroenterol. 2010; 3: 11-16.
16. Chiba N., De Gara C.J., Wilkinson J.M. et al.: Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-1810.
17. Scholten T.: Long-term management of gastroesophageal reflux disease with pantoprazole. Ther. Clin. Risk Manag. 2007; 3(2): 231-243.
18. Sachs G., Shin J.M.: The basis of differentiation of PPIs. Drugs of Today 2004; 40(supl. A): 9-14.